Price
Target price
€116.00
€116.00
-0.860%
-1.0
-0.860%
€112.48
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Protagonist Therapeutics Inc Stock
Protagonist Therapeutics Inc shows a slight decrease today, losing -€1.000 (-0.860%) compared to yesterday.
The stock is an absolute favorite of our community with 26 Buy predictions and no Sell predictions.
On the other hand, the target price of 112 € is below the current price of 116.0 € for Protagonist Therapeutics Inc, so the potential is actually -3.45%.
So far the community has only identified positive things for Protagonist Therapeutics Inc stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Protagonist Therapeutics Inc in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
M***** P*******
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Comments
Protagonist Therapeutics (PTGX) had its "buy" rating reaffirmed by TD Cowen.
Show more
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (PTGX) was upgraded by Wolfe Research to "strong-buy".
Show more
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (PTGX) is now covered by Wolfe Research. They set an "outperform" rating and a $135.00 price target on the stock.
Show more
Ratings data for PTGX provided by MarketBeat
News
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit
Hedge fund BVF reported a full exit from Protagonist Therapeutics (NASDAQ:PTGX) in its February 17, 2026, SEC filing, selling 2,560,916 shares worth an estimated $170.12 million.
According to its
Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance
On Feb. 6, 2026, William D. Waddill, a director at Protagonist Therapeutics (NASDAQ:PTGX), exercised his stock options and immediately sold 20,000 shares, generating a transaction value of
Protagonist Therapeutics Chief Medical Officer Sells PTGX 9,514 Shares for $784K to Cover Taxes
Arturo Molina, Chief Medical Officer of Protagonist Therapeutics (NASDAQ:PTGX), directly sold 9,514 shares in an open-market transaction on Jan. 20, 2026, for an approximate value of $784,700